EGFR and non-small cell lung carcinoma: First and second generation TKIs have limited efficacy in treating EGFRex20ins-positive NSCLC, however several next generation EGFR TKIs have shown pre-clinical activity against this unique subset of mutation and are currently in development, for example DZD9008 and CLN-081 (16, 17).